Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2010
Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Effects of nicotine on smooth pursuit eye movements in healthy non-smokers.Psychopharmacology · 2019Trial
- Nicotine restores functional connectivity of the ventral attention network in schizophrenia.Neuropharmacology · 2016Trial
- Neuronal effects of nicotine during auditory selective attention in schizophrenia.Human brain mapping · 2016Trial
- Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.Biological psychiatry · 2011Trial
- Intrinsic Infant Hippocampal Function Supports Inhibitory Processing.Developmental psychobiology · 2024Article
- Cholinergic Functioning, Cognition, and Anticholinergic Medication Burden in Schizophrenia.Current topics in behavioral neurosciences · 2023Review
- Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Review
- Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Article
- Bidirectional Regulation of Aggression in Mice by Hippocampal Alpha-7 Nicotinic Acetylcholine Receptors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Similar nicotinic excitability responses across the developing hippocampal formation are regulated by small-conductance calcium-activated potassium channels.Journal of neurophysiology · 2018Article
- Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.Journal of psychopharmacology (Oxford, England) · 2017Review
- Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders.Cellular and molecular life sciences : CMLS · 2016Review
- Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.Current pharmaceutical design · 2016Review
- Effect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI Studies.Frontiers in psychiatry · 2016Review
- Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.Current pharmaceutical design · 2015Review
- Neuroimaging biomarkers for early drug development in schizophrenia.Biological psychiatry · 2014Review
- Merging old and new perspectives on nicotinic acetylcholine receptors.Biochemical pharmacology · 2014Review
- Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.Current pharmaceutical design · 2014Review
- Evidence for gamma and beta sensory gating deficits as translational endophenotypes for schizophrenia.Psychiatry research · 2013Article
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Molecular psychiatry · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
3-(2,4-Dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at alpha7-nicotinic acetylcholine receptors and is now in early clinical development for treatment of deficits in neurocognition and sensory gating in schizophrenia. During its initial phase 2 test, functional magnetic resonance imaging (fMRI) studies were conducted to determine whether the drug had its intended effect on hippocampal inhibitory interneurons. Increased hemodynamic activity in the hippocampus in schizophrenia is found during many tasks, including smooth pursuit eye movements, and may reflect inhibitory dysfunction. Placebo and two doses of drug were administered in a random, double-blind crossover design. After the morning drug/placebo ingestion, subjects underwent fMRI while performing a smooth pursuit eye movement task. Data were analyzed from 16 nonsmoking patients, including 7 women and 9 men. The 150-mg dose of DMXB-A, compared with placebo, diminished the activity of the hippocampus during pursuit eye movements, but the 75-mg dose was ineffective. The effect at the 150-mg dose was negatively correlated with plasma drug levels. The findings are consistent with the previously established function of alpha7-nicotinic receptors on inhibitory interneurons in the hippocampus and with genetic evidence for deficits in these receptors in schizophrenia. Imaging of drug response is useful in planning future clinical tests of this compound and other nicotinic agonists for schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.